India to Sri Lanka: Adalimumab Export Trade Route

To import Adalimumab formulations into Sri Lanka, the following approvals and registrations are mandatory:

1. Product Registration: All pharmaceutical products must be registered with the NMRA. The application should include a comprehensive dossier, typically formatted in the Common Technical Document (CTD) or electronic CTD (eCTD) format.

2. Dossier Submission: The dossier must encompass detailed information on the product's quality, safety, and efficacy. This includes manufacturing processes, stability data, and clinical studies.

3. Approval Timelines: While specific timelines can vary, applicants are advised to submit their import license applications at least twelve (12) weeks in advance to ensure timely processing and avoid delays. (nmra.gov.lk)

4. Product Registration Fees: The NMRA imposes fees for product registration. Applicants should consult the NMRA's official fee schedule for the most current information.

5. GMP Inspection Requirements: Foreign manufacturing facilities must obtain NMRA approval. This involves submitting an application through a local authorized agent, providing a Site Master File, and undergoing a desk review. (nmra.gov.lk)

Indian manufacturers exporting Adalimumab formulations to Sri Lanka must comply with stringent Good Manufacturing Practice (GMP) standards:

This measure aims to maintain high standards of quality and safety for medicines imported into Sri Lanka. (nmra.gov.lk)

2. Approved Indian Facilities: Indian manufacturers holding the aforementioned GMP certifications are eligible to export to Sri Lanka. Specific approvals are granted on a case-by-case basis following NMRA evaluation.

3. Recent Inspections and Regulatory Actions: The NMRA conducts GMP audits of foreign manufacturing facilities as part of the approval process. (nmra.gov.lk) While specific details of recent inspections or regulatory actions against Indian pharmaceutical companies are not publicly disclosed, manufacturers are expected to maintain compliance with GMP standards to avoid potential sanctions.

Several regulatory changes have been implemented in the past 18 months affecting pharmaceutical imports into Sri Lanka:

1. Manufacturing Plant Approval Process: Effective January 1, 2025, the NMRA revised its approval process for foreign manufacturing plants. Only facilities with PIC/S, EU GMP, or WHO prequalification/approval are accepted for registration. This temporary measure aligns with WHO's reliance regulatory approach to ensure the quality and safety of imported medicines. (nmra.gov.lk)

2. Import License Application Process: Starting November 1, 2025, the NMRA requires marketing authorization holders to submit import license applications at least twelve (12) weeks in advance. Applicants must provide detailed price information using the specified format and submit it both in hard copy and via email to pricing@nmra.gov.lk. (nmra.gov.lk)

These developments underscore Sri Lanka's commitment to upholding high pharmaceutical standards and ensuring the safety and efficacy of imported medicines.

As of 2024, Sri Lanka's Adalimumab market is experiencing growth, driven by increasing prevalence of autoimmune diseases such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. The aging population and enhanced healthcare infrastructure contribute to this demand. While specific market size figures for 2024-2025 are not readily available, the import data indicates a reliance on foreign suppliers for Adalimumab formulations. Domestic production of Adalimumab is limited, necessitating imports to meet patient needs.

Sri Lanka maintains a 0% MFN import duty rate for immunological products under HS code 30021500, which includes Adalimumab formulations. This exemption aligns with the country's policy to ensure the availability of essential pharmaceuticals. Additionally, the Indo-Sri Lanka Free Trade Agreement (ISFTA) provides preferential treatment for various goods; however, specific details regarding pharmaceutical products under this agreement are not specified. There are no anti-dumping duties imposed on Adalimumab imports into Sri Lanka.

India is a significant supplier of Adalimumab formulations to Sri Lanka, accounting for 20% of India's total Adalimumab formulation exports, valued at $1.2 million. The primary Indian exporters include Reliance Life Sciences Private Limited and Aditya Life Sciences. Sri Lanka's import data indicates that the Bank of Ceylon - Trade Services is a major buyer, with imports valued at $0.2 million. While specific data on other supplying countries and their market shares are not detailed, India's proximity and established pharmaceutical industry position it as a competitive supplier. Pricing comparisons between Indian suppliers and competitors from regions like China or the European Union are not specified, but India's cost-effective manufacturing capabilities often provide a pricing advantage.

India has solidified its position as a global leader in the production of generic pharmaceuticals, including complex biologics like Adalimumab formulations. As of November 2024, India registered 376 pharmaceutical manufacturing facilities with the U.S. Food and Drug Administration (FDA), comprising 200 dedicated to active pharmaceutical ingredients (APIs) and 134 to finished dosage forms (FDFs). This extensive infrastructure underscores India's capacity to produce high-quality pharmaceutical formulations.

The country's manufacturing scale for finished dosage forms, including injections and other Adalimumab formulations, is bolstered by numerous facilities holding certifications from the World Health Organization's Good Manufacturing Practices (WHO-GMP) and approvals from the FDA. This ensures compliance with stringent international quality standards. Additionally, India's cost-effective production processes, driven by economies of scale and a skilled workforce, enable the production of Adalimumab formulations at competitive prices without compromising quality.

When comparing Adalimumab formulation exports from India, China, and the European Union (EU), several factors come into play:

• Price per Unit: In China, biosimilars of Adalimumab are priced at approximately 82% of the reference drug's cost. In contrast, India's efficient manufacturing processes often result in lower production costs, allowing for more competitively priced formulations. The EU, with its stringent regulatory environment and higher production costs, typically offers Adalimumab formulations at higher price points.

• Quality Perception: India's pharmaceutical industry is renowned for adhering to international quality standards, with numerous facilities holding WHO-GMP and FDA approvals. China has been enhancing its manufacturing standards, but perceptions regarding quality can vary. The EU maintains a strong reputation for high-quality pharmaceutical products.

• Regulatory Acceptance in Sri Lanka: Sri Lanka's National Medicines Regulatory Authority (NMRA) recognizes and accepts pharmaceuticals from manufacturers with WHO-GMP and FDA certifications, which many Indian manufacturers possess. This facilitates smoother regulatory approvals for Indian Adalimumab formulations.

• Supply Reliability Track Record: India has a consistent track record of supplying pharmaceutical formulations to global markets, including Sri Lanka. The established trade routes and logistical networks between India and Sri Lanka further enhance supply reliability.

The India-Sri Lanka supply chain for Adalimumab formulations is robust, supported by India's substantial manufacturing capacity and advanced packaging and cold chain logistics. Indian manufacturers have invested in state-of-the-art facilities to ensure the integrity of temperature-sensitive biologics during transit.

As of November 2024, India maintained 134 FDA-registered facilities dedicated to finished dosage forms, indicating significant production capacity. There have been no significant reports of supply disruptions in recent years, reflecting the reliability of Indian manufacturers. Furthermore, these manufacturers have a strong compliance record with international regulatory standards, ensuring consistent product quality.

While specific capacity constraints or expansion plans among top Indian Adalimumab formulation manufacturers are not publicly disclosed, the existing infrastructure and ongoing investments suggest a commitment to meeting global demand.

For Sri Lankan buyers aiming to source Adalimumab formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply chain.

• Minimum Order Quantities (MOQs): Indian pharmaceutical exporters typically require MOQs to optimize production and logistics. It's advisable to negotiate MOQs that align with your demand forecasts to maintain inventory efficiency.

• Payment Terms: Common payment terms in the India-Sri Lanka pharmaceutical trade include Letters of Credit (LC) and advance payments. Establish clear payment agreements to foster trust and ensure smooth transactions.

• Supplier Qualification Process: Conduct thorough due diligence on potential suppliers, including audits of manufacturing facilities, verification of regulatory certifications (e.g., WHO-GMP, FDA approvals), and assessment of their track record in international markets.

• Regulatory Compliance: Ensure that the selected Adalimumab formulations comply with Sri Lanka's NMRA requirements, facilitating seamless importation and distribution within the country.

By implementing these strategies, Sri Lankan buyers can establish a reliable and cost-effective supply chain for Adalimumab formulations sourced from India.

1. National Medicines Regulatory Authority (NMRA) Registration: Confirm that the Adalimumab formulation is registered with Sri Lanka's NMRA, as unregistered products are not permitted for importation.

2. Good Manufacturing Practice (GMP) Certification: Verify the validity of the manufacturer's GMP certificate, ensuring it aligns with WHO guidelines. (nmra.gov.lk)

3. Drug Master File (DMF) Review: Obtain and assess the DMF to evaluate the manufacturing process, controls, and quality standards of the Adalimumab formulation.

4. Quality Management System (QMS) Evaluation: Ensure the supplier has a robust QMS in place, encompassing quality control, assurance, and risk management protocols.

5. Regulatory Compliance Documentation: Request evidence of compliance with international regulatory bodies, such as the US FDA or EMA, to confirm global standards adherence.

6. Product Stability Data: Review stability studies conducted under ICH guidelines to confirm the product's shelf-life and efficacy under various conditions.

7. Track Record Assessment: Investigate the supplier's history of exporting Adalimumab formulations to global markets, indicating reliability and experience.

8. Factory Audit Arrangement: Plan for an on-site audit of the manufacturing facility to assess compliance with GMP and other quality standards.

1. Certificate of Analysis (CoA): Provides detailed results of laboratory testing for a specific batch, confirming it meets predefined specifications.

2. Certificate of Origin (CoO): Certifies the country where the product was manufactured, essential for regulatory and tariff purposes.

3. GMP Certificate: Issued by a competent authority, this certificate confirms the manufacturing facility complies with GMP standards.

4. Stability Data: Includes results from stability studies under ICH guidelines, demonstrating the product's shelf-life and storage conditions.

5. Batch Manufacturing Records: Detailed documentation of the production process for each batch, ensuring consistency and traceability.

6. Drug Master File (DMF): Comprehensive document detailing the manufacturing process, controls, and quality standards of the product.

7. Free Sale Certificate: Issued by the Central Drugs Standard Control Organization (CDSCO), indicating the product is approved for sale in the country of origin.

8. Insurance Certificates: Proof of liability insurance coverage, protecting against potential claims related to product quality or safety.

1. Regulatory Non-Compliance: Recent warning letters or sanctions from regulatory bodies like the US FDA or WHO indicate potential compliance issues.

2. GMP Certification Suspension: Suspension or revocation of GMP certification suggests significant quality management failures.

3. Unrealistically Low Pricing: Prices significantly below market rates may indicate compromised quality or substandard manufacturing practices.

4. Lack of Stability Data: Inability to provide comprehensive stability studies raises concerns about product shelf-life and efficacy.

5. Limited Export History: Absence of a track record in exporting to regulated markets may reflect inexperience or non-compliance with international standards.

6. Resistance to Audits: Hesitation or refusal to allow facility audits suggests potential issues with manufacturing practices or quality control.

1. Pre-Audit Desktop Review: Conduct a thorough review of all provided documentation, including GMP certificates, DMFs, and quality control records.

3. Post-Audit Corrective Actions: Document any deficiencies found during the audit and require the supplier to implement corrective actions within a specified timeframe.

4. Annual Re-Qualification Process: Schedule regular audits, at least annually, to ensure ongoing compliance and continuous improvement.

5. Remote Monitoring Options: Utilize virtual audits, periodic documentation reviews, and third-party inspections to maintain oversight between on-site audits.

6. Cost Estimates and Timeline: Budget approximately $5,000 to $10,000 USD for an on-site audit, including travel and accommodation expenses, with the process typically taking 3 to 5 days.

By adhering to this comprehensive supplier qualification framework, Sri Lankan companies can ensure the procurement of high-quality Adalimumab formulations from Indian manufacturers, safeguarding patient health and maintaining regulatory compliance.